

Title (en)  
Glycosaminoglycan-synthetic polymer conjugates.

Title (de)  
Glukosominoglukan-synthetische-Polymer-Konjugaten.

Title (fr)  
Conjugués de glycosominoglucanes et de polymères synthétiques.

Publication  
**EP 0656215 A1 19950607 (EN)**

Application  
**EP 94117227 A 19941101**

Priority  
US 14684393 A 19931103

Abstract (en)  
Pharmaceutically acceptable, nonimmunogenic compositions are formed by covalently binding glycosaminoglycans or derivatives thereof, to hydrophilic synthetic polymers via specific types of chemical bonds to provide biocompatible conjugates. Useful glycosaminoglycans include hyaluronic acid, the chondroitin sulfates, keratan sulfate, chitin and heparin, each of which is chemically derivatized to react with a hydrophilic synthetic polymer. The conjugate comprising a glycosaminoglycan covalently bound to a hydrophilic synthetic polymer may be further bound to collagen to form a three component conjugate having different properties. The hydrophilic synthetic polymer may be polyethylene glycol and derivatives thereof having an average molecular weight over a range of from about 100 to about 100,000. The compositions may include other components such as fluid, pharmaceutically acceptable carriers to form injectable formulations, and/or biologically active proteins such as growth factors or cytokines.

IPC 1-7  
**A61K 47/48**; **A61L 27/00**; **A61L 31/00**

IPC 8 full level  
**A61K 47/48** (2006.01); **A61L 24/10** (2006.01); **A61L 26/00** (2006.01); **A61L 27/00** (2006.01); **A61L 27/18** (2006.01); **A61L 27/20** (2006.01); **A61L 27/24** (2006.01); **A61L 27/26** (2006.01); **A61L 27/34** (2006.01); **A61L 27/44** (2006.01); **A61L 27/54** (2006.01); **A61L 29/04** (2006.01); **A61L 29/06** (2006.01); **A61L 29/16** (2006.01); **A61L 31/04** (2006.01); **A61L 31/10** (2006.01); **A61L 31/12** (2006.01); **C07K 14/495** (2006.01); **C07K 14/78** (2006.01); **C08B 37/00** (2006.01); **C08B 37/08** (2006.01); **C08H 1/06** (2006.01); **C08L 89/06** (2006.01); **C09J 189/06** (2006.01); **A61F 2/00** (2006.01); **A61F 2/06** (2006.01); **A61K 38/00** (2006.01)

CPC (source: EP US)  
**A61K 47/60** (2017.07 - EP US); **A61K 47/61** (2017.07 - EP US); **A61K 47/6435** (2017.07 - EP US); **A61L 24/102** (2013.01 - EP US); **A61L 26/0033** (2013.01 - EP US); **A61L 27/18** (2013.01 - EP US); **A61L 27/20** (2013.01 - EP US); **A61L 27/24** (2013.01 - EP US); **A61L 27/26** (2013.01 - EP US); **A61L 27/34** (2013.01 - EP US); **A61L 27/44** (2013.01 - EP US); **A61L 27/54** (2013.01 - EP US); **A61L 29/043** (2013.01 - EP US); **A61L 29/045** (2013.01 - EP US); **A61L 29/06** (2013.01 - EP US); **A61L 29/16** (2013.01 - EP US); **A61L 31/041** (2013.01 - EP US); **A61L 31/042** (2013.01 - EP US); **A61L 31/044** (2013.01 - EP US); **A61L 31/10** (2013.01 - EP US); **A61L 31/125** (2013.01 - EP US); **C07K 14/495** (2013.01 - EP US); **C07K 14/78** (2013.01 - EP US); **C08B 37/0069** (2013.01 - EP US); **C08B 37/0072** (2013.01 - EP US); **C08H 1/06** (2013.01 - EP US); **C08L 89/06** (2013.01 - EP US); **C09J 189/06** (2013.01 - EP US); **A61F 2/07** (2013.01 - EP US); **A61F 2310/00365** (2013.01 - EP US); **A61K 38/00** (2013.01 - EP US); **A61L 2300/236** (2013.01 - EP US); **A61L 2300/252** (2013.01 - EP US); **A61L 2300/414** (2013.01 - EP US); **A61L 2300/802** (2013.01 - EP US); **A61L 2430/16** (2013.01 - EP US); **C08L 2666/02** (2013.01 - EP US); **Y10S 525/937** (2013.01 - EP US)

Citation (search report)  
• [X] WO 8910728 A1 19891116 - MASSACHUSETTS INST TECHNOLOGY [US]  
• [PXD] WO 9401483 A1 19940120 - COLLAGEN CORP [US]  
• [X] WO 9216221 A1 19921001 - SYNERGEN INC [US]  
• [X] WO 9316658 A1 19930902 - JSF CONSULTANTS LTD [US]  
• [AP] FR 2694894 A1 19940225 - COLETICA [FR]  
• [PX] WO 9403155 A1 19940217 - GEN HOSPITAL CORP [US]  
• [A] WO 9202238 A1 19920220 - BASS LAWRENCE SAMUEL [US], et al  
• [XP] CHEMICAL ABSTRACTS, vol. 121, no. 16, 17 October 1994, Columbus, Ohio, US; abstract no. 181545 & JP H06102229 A 19940415 - DAIKIN IND LTD  
• [X] DATABASE WPI Section Ch Week 0789, Derwent World Patents Index; Class A96, AN 89-051979

Cited by  
AU2020256324B2; DE19729279A1; EP3750568A1; EP0697218A3; US6497729B1; US11058796B2; US11833269B2; WO9722371A1; WO03028781A1; WO03090765A1; WO2004093887A1; WO0030698A1; WO0004939A1; EP0713707A1; US7863256B2; US7884087B1; US8575129B2; US7238677B2; US11484627B2; US10857261B2; US11351261B2; US11878092B2; US6406687B1; US9308301B2; US11298444B2; EP2049572A1; WO2021041231A1; US10525169B2; US10028776B2; US10517654B2; EP2892575B1; US6193752B1; US10525168B2; US11207109B2; US11291483B2

Designated contracting state (EPC)  
AT BE CH DE DK ES FR GB IT LI NL SE

DOCDB simple family (publication)  
**EP 0656215 A1 19950607**; CA 2134745 A1 19950504; JP H07278203 A 19951024; US 5470911 A 19951128; US 5476666 A 19951219; US 5510121 A 19960423; US 5510418 A 19960423

DOCDB simple family (application)  
**EP 94117227 A 19941101**; CA 2134745 A 19941031; JP 27155694 A 19941104; US 14684393 A 19931103; US 43365695 A 19950504; US 43472595 A 19950504; US 43495895 A 19950504